Institut fuer Klinische Transfusionsmedizin Jena gGmbH
- Address
- Am Klinikum 1, Lobeda, 07747 Jena, Germany
Neoplasms
The department of Hematology and Internal Oncology at Institut fuer Klinische Transfusionsmedizin Jena gGmbH is conducting trials aimed at improving outcomes for patients with blood‑derived cancers, focusing on innovative strategies to achieve deeper remission.
- Assessment of minimal residual disease using flow cytometry and sequencing
- Evaluation of response criteria based on IMWG standards
- Stratified first‑line therapy approaches
- Integration of genomic risk scoring
These studies seek to validate new treatment protocols that could become standard care for individuals with multiple myeloma.
Immune System Diseases
Research on chronic graft‑versus‑host disease at the Jena center explores novel combination regimens to reduce disease activity and enhance quality of life for transplant survivors.
- Combination of targeted antibodies with kinase inhibitors
- Preliminary efficacy assessment of new immunomodulators
- Monitoring of organ‑specific involvement
- Patient‑reported outcome measures
The trial aims to determine how adding axatilimab to existing therapy can improve therapeutic response in chronic graft‑versus‑host disease patients.
Hemic and Lymphatic Diseases
The site’s hematology program extends its focus beyond myeloma to broader blood and lymphatic disorders, investigating biomarkers that predict treatment success.
- Biomarker discovery for disease progression
- Flow‑based detection techniques
- Correlation of blood counts with clinical outcomes
- Long‑term safety monitoring
By advancing diagnostic tools, the research supports more personalized care for individuals with hematologic malignancies.
Cardiovascular Diseases
Although the primary trials involve hematologic conditions, the institute maintains expertise in cardiovascular health, preparing to integrate vascular assessments in future oncology studies.
- Cardiac function monitoring during therapy
- Evaluation of thrombotic risk in cancer patients
- Cross‑disciplinary collaboration with cardiology
- Implementation of non‑invasive imaging
This forward‑looking approach ensures that patients receiving intensive treatments are protected against potential cardiovascular complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut fuer Klinische Transfusionsmedizin Jena gGmbH
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | Incyte Corp. | Phase II | Not Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Axatilimab | 1 | Unknown | 2024-10-22 | 2024-10-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.